EyeBio targets registrational trial after early success of Wnt agonist in retinal diseases

Eye­Bio’s tri-spe­cif­ic Wnt ag­o­nist an­ti­body im­proved vi­su­al and anatom­i­cal mea­sures in a Phase Ib/IIa tri­al as a monother­a­py and in com­bi­na­tion with Re­gen­eron’s Eylea, prompt­ing pre­lim­i­nary plans for a po­ten­tial reg­is­tra­tional study in reti­nal dis­eases.

The biotech’s lead can­di­date Re­storet is de­signed to elim­i­nate leak­age in vas­cu­lar eye dis­eases by ac­ti­vat­ing the Wnt path­way to re­store and main­tain the blood-reti­nal bar­ri­er. The Phase Ib/IIa AMARONE tri­al was stopped ear­ly due to Re­storet’s promis­ing ef­fi­ca­cy and safe­ty, CEO David Guy­er told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.